5-Methoxyflavone ameliorates non-alcoholic fatty liver disease through targeting the cytochrome P450 1A1

This publication has 41 references indexed in Scilit:

• The association between CYP1A1 genetic polymorphisms and coronary artery disease in the Uygur and Han of China
  Lipids in Health and Disease, 2014
• Cytochrome P450 Family 1 Inhibitors and Structure-Activity Relationships
  Molecules, 2013
• Methoxyflavone derivatives modulate the effect of TRAIL-induced apoptosis in human leukemic cell lines
  Journal of Hematology & Oncology, 2011
• Quantification of the effect of energy imbalance on bodyweight
  The Lancet, 2011
• Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic, and Clinical Implications
  Hepatology, 2010
• Cytochromes P450 from family 4 are the main omega hydroxylating enzymes in humans: CYP4F3B is the prominent player in PUFA metabolism
  Journal of Lipid Research, 2008
• Cancer chemopreventive properties of orally bioavailable flavonoids—Methylated versus unmethylated flavones
  Biochemical Pharmacology, 2007
• Oxidant Stress and Antioxidant Status Among Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
  Journal of Clinical Gastroenterology, 2006
• Methylation protects dietary flavonoids from rapid hepatic metabolism
  Xenobiotica, 2006
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
  Hepatology, 2005